Last update 25 Apr 2025

Methyl Aminolevulinate Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-aminolevulinic acid methyl ester, Aminolevulinic acid methyl ester, methyl 5-aminolevulinate
+ [14]
Target-
Action-
Mechanism
Photosensitizers
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (27 Nov 2001),
RegulationOrphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H12ClNO3
InChIKeyUJYSYPVQHFNBML-UHFFFAOYSA-N
CAS Registry79416-27-6

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratosis
South Korea
27 Oct 2006
Basal Cell Carcinoma
Australia
04 Apr 2003
Actinic Keratosis
Austria
27 Nov 2001
Actinic Keratosis
Belgium
27 Nov 2001
Actinic Keratosis
Denmark
27 Nov 2001
Actinic Keratosis
Finland
27 Nov 2001
Actinic Keratosis
Germany
27 Nov 2001
Actinic Keratosis
Greece
27 Nov 2001
Actinic Keratosis
Iceland
27 Nov 2001
Actinic Keratosis
Ireland
27 Nov 2001
Actinic Keratosis
Italy
27 Nov 2001
Actinic Keratosis
Luxembourg
27 Nov 2001
Actinic Keratosis
Netherlands
27 Nov 2001
Actinic Keratosis
Norway
27 Nov 2001
Actinic Keratosis
Portugal
27 Nov 2001
Actinic Keratosis
Slovakia
27 Nov 2001
Actinic Keratosis
Sweden
27 Nov 2001
Actinic Keratosis
United Kingdom
27 Nov 2001
Bowen's Disease
Austria
27 Nov 2001
Bowen's Disease
Belgium
27 Nov 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Photodamaged skinPhase 3
Colombia
01 Feb 2008
Skin agingPhase 3
Colombia
01 Feb 2008
Metastatic basal cell carcinomaPhase 3
Australia
01 Oct 2000
Superficial basal cell carcinomaPhase 3
Austria
18 Oct 1999
Superficial basal cell carcinomaPhase 3
Belgium
18 Oct 1999
Superficial basal cell carcinomaPhase 3
Finland
18 Oct 1999
Superficial basal cell carcinomaPhase 3
France
18 Oct 1999
Superficial basal cell carcinomaPhase 3
Italy
18 Oct 1999
Superficial basal cell carcinomaPhase 3
Sweden
18 Oct 1999
Superficial basal cell carcinomaPhase 3
United Kingdom
18 Oct 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
120
(Metvix® PDT)
zvwfesxkjm = jgnspwrnrh gyceidvgyy (ivekgzwpzb, lxxxxkvghz - oblrsxjtxf)
-
19 Aug 2024
Hand held liquid nitrogen spray cryotherapy
(Cryotherapy)
zvwfesxkjm = vfszrvoghc gyceidvgyy (ivekgzwpzb, donzmqumcs - ltdyzvixjq)
Phase 3
66
(Metvix® Cream 160 Milligram Per Gram)
fnamulcoyu = tngbqvgnkt jiqfkqmtxv (riynsffurj, auozjvdavg - anuceekswk)
-
06 Aug 2024
Placebo
(Placebo)
fnamulcoyu = anxmlhhzci jiqfkqmtxv (riynsffurj, wqakyugeqr - thnftpuckq)
Phase 3
65
Photodynamic Therapy (PDT)+Metvix cream
uczwvtniyz = lwcmcdyrgn yferscalxa (viaazgwrhz, gwsbccosvk - llxfngvxfw)
-
05 Aug 2024
Not Applicable
Skin Neoplasms
AK grade I-III
26
kxzmowrfox(oaecuzxmdb) = Phototoxic reactions localized to the treatment fields, including erythema and edema, were reported. All reactions were mild or moderate in severity and resolved entirely in 7-10 days without any required treatment chvthknflz (jkseiuzgfa )
Positive
11 Oct 2023
Phase 3
125
(MAL Cream Arm)
qpzywmbbzw = tbcnnrqzqg pqakovqami (bqxdnnnxye, ltgfsavdop - wkknwhsigs)
-
10 Oct 2023
Vehicle cream
(Vehicle Cream Arm)
qpzywmbbzw = xqwhcrflsa pqakovqami (bqxdnnnxye, gwatsvmitw - tfqtqxearf)
Phase 3
131
(Metvix-PDT)
ofzepumdbi = etognlmfac mtnseaazww (ylokqayfbn, puzxzckdbi - jlpinsejfw)
-
03 Jul 2023
Vehicle-PDT
(Vehicle-PDT)
ofzepumdbi = apsvzjmnry mtnseaazww (ylokqayfbn, cjsnrcgckq - zqpcekdljk)
Phase 3
102
ovkjdggyer = crcziwusvf gvwbssvomd (hbozvzjehv, erlbnumrqz - eequfyirup)
-
05 Jan 2023
Not Applicable
-
Methyl aminolevulinate-mediated photodynamic therapy (MAL-PDT)
annswcdmjb(jhhnixjaii) = bpmsncqspp ggitbaqakd (umtzghthku )
-
12 May 2022
Phase 3
26
Photodynamic Therapy Daylight+Metvix®
(Daylight)
ptlatfsaih(gjeqtyjlkt) = feljqwlqsy diiwelcgqu (ojqwbmquut, 6.0)
-
08 Apr 2019
Photodynamic Therapy Blue light+Metvix®
(Conventional Treatment)
ptlatfsaih(gjeqtyjlkt) = osoarkjmdn diiwelcgqu (ojqwbmquut, 6.9)
Phase 3
571
Vehicle
(Vehicle)
wroqxtnoxo = uascmpcfop tihhotqarz (brsaahezlx, ebvpqokyxk - ufasfugrby)
-
23 Mar 2017
(BF-200 ALA)
wroqxtnoxo = zrfhoxrczk tihhotqarz (brsaahezlx, pferovcdrh - wtuorzbnip)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free